Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 71

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 71
---
 inputs (Level
3) for the nine months ended September 30, 2025 (Successor), for the period from January 1, 2024 through February 13, 2024 (Predecessor),
for the three months ended September 30, 2024 (Successor), and for the period from February 14, 2024 through September 30, 2024 (Successor)
for the Company is presented below:

| Preferred stock warrant liability (Predecessor): |     | Level 1 |   |     | Level 2 |   |     | Level 3 |            |   |     | Total |            |   |
|:-------------------------------------------------|:----|:--------|:--|:----|:--------|:--|:----|:--------|-----------:|:--|:----|:------|-----------:|:--|
| Balance at December 31, 2023                     |     | $       | - |     | $       | - |     | $       |    320,117 |   |     |       |    320,117 |   |
| Reclassification of warrant liability to equity  |     |         | - |     |         | - |     |         |   (320,117 | ) |     |       |   (320,117 | ) |
| Balance at February 13, 2024                     |     | $       | - |     | $       | - |     | $       |          - |   |     | $     |          - |   |
| Earnout liability (Successor):                   |     |         |   |     |         |   |     |         |            |   |     |       |            |   |
| Balance at June 30, 2024                         |     | $       | - |     | $       | - |     | $       |    200,000 |   |     | $     |    200,000 |   |
| Gain on revaluation of earnout liability         |     |         | - |     |         | - |     |         |   (170,000 | ) |     |       |   (170,000 | ) |
| Balance at September 30, 2024                    |     | $       | - |     | $       | - |     | $       |     30,000 |   |     | $     |